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ABSTRACT Several lines of evidence
suggest that nonspecific drug interac-
tion with the lipid bilayer plays an impor-
tant role in subsequent recognition and
binding to specific receptor sites in the
membrane. The interaction of Bay K
8644, a 1,4-dihydropyridine (DHP) cal-
cium channel agonist, with model and
biological membranes was examined
at the molecular level using small angle
x-ray diffraction. Nonspecific drug par-
titioning into the membrane was exam-
ined by radiochemical assay. Nonspe-
cific binding characteristics of 13HI Bay
K 8644 were determined in both dipal-
mitoyl phosphatidylcholine (DPPC) ves-
icles above and below their thermal
phase transition (Tm) and rabbit skele-
tal muscle light sarcoplasmic reticulum
(LSR). In DPPC, the partition coeffi-
cient, Kp, was 14,000 above the Tm
(550C) versus 160 in the gel phase
(20C). The Kp determined in LSR mem-
branes was 10,700. These values for
both DPPC and LSR membranes can
be compared with Kp = 290 in the
traditional octanol/buffer system.
Using small-angle x-ray diffraction,
the equilibrium position of the electron-
dense trifluoromethyl group of Bay K
8644 in DPPC (above Tm) and purified
cardiac sarcolemmal (CSL) lipid bi-
layers was determined to be consis-
tently located within the region of the
first few methylene segments of the
fatty acyl chains of these membranes.
This position is similar to that observed
for the DHP calcium channel antago-
nists nimodipine and Bay P 8857. We
suggest this particular membrane loca-
tion defines a region of local drug
concentration and plane for lateral dif-
fusion to a common receptor site.
Below the DPPC membrane Tm, Bay K
8644 was shown to be excluded from
this energetically favored position into
the interbilayer water space. Heating
the DPPC bilayer above the Tm (55°C)
showed that this exclusion was revers-
ible and indicates that drug-membrane
interaction is dependent on the bilayer
physical state. The absence of any
specific protein binding sites in these
systems allows us to ascertain the
potentially important role that the bulk
lipid phase may play in the molecular
mechanism of DHP binding to the spe-
cific receptor site associated with the
calcium channel.
INTRODUCTION
1,4-DHP calcium channel antagonists and agonists play
an important role in the excitation-contraction mecha-
nism of cardiac and smooth muscle by modulating the
transmembrane influx of extracellular calcium (for
review see Janis et al., 1987). This class of calcium
channel blockers have been shown to bind with both
specificity and high affinity to protein receptors in a
variety of cell types. Bay K 8644, a potent DHP calcium
channel agonist, has a positive inotropic effect on smooth
and cardiac muscle contraction (Schramm et al., 1983).
It binds to receptors in rabbit ventricular membranes with
an apparent equilibrium dissociation constant (Kd) of 2.4
nM (Janis et al., 1984). Competitive binding studies
demonstrate that Bay K 8644 is displaced from its
high-affinity binding site by the calcium channel antago-
nist nitrendipine with a K, of 0.1 nM and an apparent Hill
slope of 0.98 (Janis et al., 1984), suggesting a common
high-affinity binding site for the calcium channel agonist
and antagonist (see also Hamilton et al., 1987). Other
specific binding studies, however, indicate separate bind-
ing sites for the agonist and antagonist (Kokubun et al.,
1986).
A mechanism for DHP binding to their specific protein
receptor has been described by Rhodes et al. (1985). This
pathway involves the DHP partitioning into the mem-
brane bilayer where it assumes an energy favorable
position and orientation before rapidly diffusing in a
plane defined by that position to a specific receptor-
binding site. Calculated, diffusion-limited rates for the
membrane pathway are approximately three orders of
magnitude greater than a direct aqueous approach of
binding for the DHP. High partition coefficients for
several DHPs with Kp ranging from 5,000 to 150,000
(Herbette et al., 1986) and low DHP receptor density in
the cardiac sarcolemma of one receptor per square micron
(Colvin et al., 1985) makes DHP nonspecific interaction
with the membrane highly probable. Further, rapid lat-
eral diffusion for an active DHP analogue (Chester et al.,
1987), specific binding studies (Affolter and Coronado,
1985; Valdivia and Coronado, 1988) and patch-clamp
investigations (Kokubun and Reuter, 1985) have pro-
vided experimental support for the membrane bilayer
pathway for DHP binding to its receptor.
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Genetic studies have implicated a specific binding site
in the transmembrane portion of the beta-adrenergic
receptor (Kobilka et al., 1987b, 1988). Previous neutron
diffraction studies have observed the location of the beta
adrenergic antagonist propranolol (Herbette et al., 1983)
to be near the hydrocarbon core/water interface of lipid
bilayer membranes. This position may in turn define a
region of localized drug concentration in equilibrium with
the high-affinity receptor site buried in the membrane.
The primary structure of the DHP receptor from rabbit
skeletal muscle has been deduced from its DNA
sequences (Tanabe et al., 1987). The polypeptide is
structurally very similar to the voltage-dependent sodium
channel with four units of high homology that putatively
comprise six transmembrane alpha helices and may serve
as the channel for calcium (Tanabe et al., 1987). Similar
to that suggested for the beta-adrenergic receptor (Ko-
bilka et al., 1988), the transmembrane helices of the
calcium channel may be critical for the binding of highly
lipophilic DHPs.
In the present study we asked whether the calcium
channel agonist Bay K 8644 occupies the same region in
the CSL lipid bilayer as the antagonist Bay P 8857.
Structural analysis of the interaction of Bay K 8644 with
purified CSL and DPPC multilamellar vesicles, com-
bined with the kinetics of nonspecific binding of the drug
to rabbit LSR and DPPC vesicles have been used to
examine the so called "nonspecific" membrane interac-
tions of the drug. Bay K 8644 contains an ortho trifluo-
romethyl substituent to the phenyl ring, whereas Bay P
8857 has an iodoethylester group extending from the 5'
carboxylate substituent of the pyridine ring. The high
electron density of these halogen substituents, in contrast
to the lipid bilayer, allows the time-averaged position of
the ligand in the membrane bilayer to be determined by
small angle x-ray diffraction. The effect of the lipid phase
on drug partitioning and membrane location was exam-
ined with the DPPC bilayers above and below its thermal
phase transition (Tm). The equilibrium partition coeffi-
cient of [3H] Bay K 8644 in LSR against buffer was also
investigated. These results suggest that the nonspecific
interactions of Bay K 8644 with the membrane bilayer
may result in a well-defined location, orientation, and
conformation necessary for intrabilayer receptor bind-
ing.
METHODS AND MATERIALS
Chemicals
Bay K 8644 and Bay P 8857 were gifts from Miles Laboratories Inc.,
New Haven, CT. [3H]Bay K 8644 (66.9 Ci/mmol) was obtained from
New England Nuclear Corp., Boston, MA. The labeled drug was stored
in the dark at - 120C. Unlabeled drug was stored at 40C, in the dark.
Both drugs were dissolved in 100% ethanol due to their limited aqueous
solubility. Dipalmitoylphosphatidylcholine was purchased from Avanti
Biochemicals, Birmingham, AL, and stored in powder form at 40C. Bay
P 8857 was used after recrystallization, and drug and lipid purity was
examined by thin-layer chromatography (TLC) before and after dif-
fraction experiments to verify structural integrity. All other chemicals
were reagent grade and any solutions were made using glass distilled
deionized water.
Skeletal sarcoplasmic reticulum
and cardiac sarcolemmal
membrane isolation and
lipid preparation
Purified LSR membranes were isolated from rabbit skeletal muscle as
previously described (Watras et al., 1984). Crude canine cardiac
sarcolemmal membranes were isolated by the method of Jones et al.
(1980). Lipids were extracted from these CSL preparations essentially
by the method of Folch et al. (1957). CSL lipid extraction and analytical
procedures have been described in full detail in a previous communica-
tion (Chester et al., 1987). Lipid phosphorus was determined by a
modification of the method of Chen et al. (1956) as described previously
(Chester et al., 1987). Polar and neutral lipid composition was analyzed
by TLC on 250 Am silica gel 60 TLC plates (EM Reagents, E. Merck,
Darmstadt, FRG) by developing -15 cm in a single dimension with
chloroform:methanol:20% methylamine:water (60:36:10:0.3, vol/vol) to
resolve the polar lipids with subsequent development (20 cm) in the
same direction with benzene:diethylether:ethanol:28% ammonia
(50:40:2:0.1, vol/vol) to resolve the neutral lipids. The various lipid
classes were visualized under longwave UV light after staining with the
fluorescent spray reagent, 1 mM 2-p-toluidinyl-6-naphthalenesulfonate
(TNS, Eastman Kodak Co., Rochester, NY) in 50 mM Tris:HC1, pH
7.5. Lipid class composition was assessed by scanning TNS fluorescence
with a model SL-2DUV soft laser scanning densitometer (Zeineh
Biomedical Instruments, Inc., Fullerton, CA) or scraping of bands for
phosphate assay.
The phospholipid composition of the CSL membranes was primarily
phosphatidylcholine (45%) and phosphatidylethanolamine (36%) with
lesser amounts of phosphatidylserine and sphingomyelin (8%), phospha-
tidylinositol (7%), and phosphatidylglycerol (1%). Cholesterol
accounted for 13 mol% of the phospholipid content.
Multilamellar vesicle preparation
CSL multilamellar lipid vesicles were prepared in the presence or
absence of known amounts of Bay K 8644 and Bay P 8857 essentially by
the method of Bangham (1965). A specified volume of 0.5 mM Hepes,
pH 7.27, 2 mM NaCl buffer containing the drug was added to the dried
lipid preparation yielding a final drug-to-lipid ratio of 1:35 or 1:40.
DPPC multilamellar vesicles were prepared as follows. The desired
amount of lipid dissolved in CHCI3:MeOH (19:1) was placed in a glass
test tube and dried down to a thin film under N2. Buffer (0.5 mM Hepes,
2.0 mM NaCl, pH 7.27), in the presence and absence of known Bay K
8644 and Bay P 8857 concentrations, was added to provide a final lipid
concentration of 5 mg/ml. This solution was then sonicated above its Tm
(480C) to form a cloudy white suspension of multilamellar vesicles as
assayed by electron microscopy. The membrane samples were stored at
40C until use.
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Preparation of multibilayer
samples for x-ray diffraction
Multilayer samples were prepared as described in detail (Chester et al.,
1987). Briefly, 50 ,1 of the multilamellar vesicle preparation described
above was added to lucite sedimentation cells containing an aluminum
foil substrate. The vesicles were sedimented onto the substrate at 85,000
g for 30 min in an SW-28 rotor. The normal bucket caps were then
replaced with the "spin dry caps", which have a single 100-,um-diameter
hole in the top (Chester et al., 1987), and the pelleted vesicles spin dried
at 65,000 g for 4 h. On completion of the spin dry process, the samples
were mounted on curved glass supports and rehydrated in sealed brass
canisters containing a saturated salt solution to define a specific relative
humidity.
The salts used for controlling humidity were LiCl, 13%; MgCl, 32%;
NaNO2, 66%; (NH4)2SO4, 81%; and ZnSO4, 93%.
Small angle x-ray diffraction with
multibilayer samples
Small-angle x-ray diffraction studies were carried out by aligning the
samples at near grazing incidence with respect to the x-ray beam. The
radiation source was a collimated, monochromatic x-ray beam (CuKa
x-ray, X = 1.54 A) from an Elliott GX-18 rotating anode x-ray genera-
tor (Marconi Avionics, Ltd., Borehamwood, UK). The experimental
method utilized a single Franks' mirror defining a line source where K,.,
and K.2 are unresolved. Sample temperature was controlled for the
diffraction experiments. Upon completion of data collection, lipid and
drug integrity were assessed by TLC.
Diffraction data collection
and reduction
The data were recorded on both Kodak DEF-5 film (Eastman Kodak
Co.) and a Braun position-sensitive 1-D detector (Innovative Technolo-
gies, Inc., South Hamilton, MA). Relative intensities for the diffraction
orders were obtained either by scanning x-ray films with a Zeineh model
SL-2DUV soft laser scanning densitometer (Biomed Instruments Inc.,
Fullerton, CA) or directly from digitized computer plots of the detector
data using an integration routine. After repeated cycles of data reduc-
tion, the systematic error was determined to be <5% of the integrated
intensities for each of the diffraction orders I (h = 1-6 for CSL and
h = 1-7 for DPPC). To examine the effect of the systematic error, we
recalculated electron density profiles for all the data with random 5%
changes (increase or decrease) in all the diffraction orders. Whereas this
deliberate 5% random error in the values of the integrated intensities
modulated the electron density profiles, the differences observed
between the sample with and without drug were preserved and did not
affect the interpretation of the data. Thus, based on the signal to noise of
our data, experimental uncertainty in the data and the potential for
introducing errors based on how we integrate the various lamellar
reflections, the changes that we have observed appear to be meaningful
and are self-consistent when comparing different membrane lipid sam-
ples.
Data reduction (background and other geometrical corrections) for
either method of data collection has been described previously (Herbette
et al., 1985a). The lamellar intensity functions from the cardiac
sarcolemmal samples collected with the electronic detector were correc-
ted by a factor of s2 = (2 sin O/X)'. The Lorentz correction factor (one
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FIGURE 1 (A) D/2 shift in the experimental electron density profiles of
DPPC membranes below their thermal phase transition (15C) in the
absence ( ....) and presence (-) of Bay K 8644 in a 1:37.5 drug:lipid
ratio at 81% relative humidity (9 A resolution). The phosphate atom of
the headgroup is labeled with a "P." Superimposition of these profiles
demonstrate that they are identical within experimental error except for
an increase in electron density in the interbilayer water space (---) when
the bilayer is in the gel state. The unit cell repeat distance is 61 A for the
bilayers. This observation was independent of hydration (13-93%); 80
correction factor applied to data. (B) Same as A but with a correction
factor of s' applied to the data for samples with and without drug.
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FIGURE 2 D/2 shift in the experimental electron density profiles of DPPC membranes above their thermal phase transition (550C) in the absence
( .) and presence (-) of Bay K 8644 in a 1:37.5 drug:lipid ratio at 81% relative humidity (four diffraction orders for 14 A resolution). There was
a 0.9-A decrease in the unit cell repeat distance for the DPPC in the presence of Bay K 8644 relative to the control. When superimposing these profiles
with a unit cell repeat of 52 A, there is no significant change beyond experimental error of electron density in the interbilayer water space as seen in
Fig. 1. The only statistically significant change in electron density is an increase within the bilayer as marked by the arrows and consistent with CSL as
well as DOPC in the liquid crystalline state (data not shown). This drug location in DPPC above the thermal phase transition was observed over a
variety of relative humidities. This change in electron density from the interbilayer water space to within the bilayer as a function of bilayer state is
reversible; 80 correction factor applied to data. (B) Same as A but with a correction factor of s' applied to the data for samples with and without
drug.
factor of s) arises from the cylindrical curvature of the multilayers and
hence is a weighting function for the intersection of the reciprocal lattice
of the multilayer with the Ewald sphere. The second factor of s was
necessary because the CSL lamellar diffraction arcs were significantly
larger than the height of the detector window due to the inherent mosaic
spread of the membrane multilayer samples. The second factor of s was
further confirmed by comparing the electron density profiles calculated
from data collected on the electronic detector where the lamellar
scattering function was corrected by s2 with electron density profiles
calculated from data obtained on film where the entire reflection arc
was integrated and corrected by s'.
The inherent mosaic spread of the lamellar intensity for DPPC lipid
samples was significantly smaller and thus a correction factor of S2
resulted in electron density profiles with excessive rippling, indicative of
overcorrection of the data. In addition, using an approximate correction
of s' (the Lorentz correction factor) resulted in a somewhat overcorrec-
tion of the data (Figs. 1 B and 2 B). With no correction factor applied
(Fig 1 A and 2 A) the electron density profile is considerably damped,
indicating the data is somewhat undercorrected. Therefore, the true
correction factor for the DPPC data appears to be some value of s raised
to a fractional power >0 but < 1. We present in Figs. 1 and 2 DPPC data
with a correction factor of s° and s'. It should be noted that whereas the
correction factors modulated the shape of the various electron density
profiles, the differences attributed to the presence of the drug were
preserved as long as the correction factors were applied identically to the
control and drug sample data.
Phasing the data
To phase the lamellar reflections for each experiment, a hydration series
or swelling analysis was carried out (Moody, 1963). We used three sets
of intensity data at different relative humidities each with unique unit
cell repeat distances to assign an unambiguous phase combination to the
experimentally obtained structure factors. An algorithm devised by
Stamatoff and Krimm (1976) was used to compute the delta values for
all possible phase combinations with the most probable profile structure
possessing the least deviation (Herbette et al., 1985a).
Modeling of electron
density profiles
Step-function equivalent profiles with step widths constrained by the
resolution of the experimental data were fitted to the experimental
profile to examine perturbations in the electron density of the membrane
due to the addition of the halogenated drugs. The calculated step-
function equivalents were Fourier-transformed once to generate the
continuous structure factor function, which was truncated at a resolu-
tion equivalent to the experimental data (six diffraction orders). When
the calculated profile structure and its intensity function correlated,
within experimental error, with the experimental profile structure, the
calculations were terminated (Herbette et al., 1985b).
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Partition coefficient
measurements
The nonspecific binding of Bay K 8644 to isolated LSR membranes was
determined by centrifugation of various concentrations of [3H] Bay K
8644 as explained in detail by Herbette et al. (1988). Briefly, the
membrane partition coefficients were determined by suspending the SR
membrane vesicles (12.5 ,g/ml) in buffer (10 mM Tris, 150 mM
NaCi), pH 7.3, containing a specific drug concentration. The samples
were centrifuged in polyethylene microcentrifuge tubes (400 ,l) in a
model SW28 swinging bucket rotor (Beckman Instruments Inc., Fuller-
ton, CA) for 1 h at g., = 81,000 at 50C. Control experiments contained
the same reaction mixture, but were not centrifuged. The tip of the
centrifuge tube containing the membrane pellet was cut off; the excess
water above the pellet was blotted dry and placed in scintillation fluid to
be counted for 3H radioactivity. The question of how much of the drug is
in the membrane bilayer versus water in the interbilayer or intravesicu-
lar spaces of the pellet was addressed in a previous paper with the more
hydrophilic drugs propranolol and timolol (Herbette et al., 1983). When
comparing the amount of drug or number of counts associated with
phospholipid in the pellet (determined by phosphate assay) with the
amount of drug associated with the aqueous supernatant, it is clear that
for partition coefficients > 103, most of the drug is associated with lipid
and not buffer. In fact, after blotting the membrane pellet, only 5-10%
of the pellet's total mass represents water (Herbette et al., 1983).
The tip of the control tubes were also cut off at the same location,
blotted to remove excess buffer, and counted. These counts represented
the amount of drug nonspecifically bound to the surface of that portion
of the tube. Control counts were subtracted from the total pellet counts
to give the actual counts reflecting drug associated only with the
membrane pellet.
The amount of labeled and nonlabeled drug added to each centrifuge
tube was corrected to account for any loss of drug during transfer from
the reaction mixtures to the microcentrifuge tubes. The free drug
concentration to which the membrane vesicles were exposed during
centrifugation was determined by correcting for the total amount of
drug added to the tubes, i.e., the amount of drug remaining in the
supernatant after binding to the walls of the centrifuge tube, calculated
using the labeled drug specific activity (adjusted for counter effi-
ciency).
Membrane partition coefficients were calculated using the following
equation: (grams of drug bound to membrane/grams lipid)/(grams of
drug in supernatant/grams buffer). The amount of drug in the pellet
(bound to membrane) and in the supernatant were determined as
described above. The amount of lipid was adjusted for the recovery of
membrane in the pellet after centrifugation. The Bay K 8644 partition
coefficient was obtained using drug concentrations over the range of
10-, to lO,0OM.
K 8644 in DPPC was highly dependent on the state of the
membrane such that below its thermal phase transition
(2°C), the Kp was 160 ± 520 while in the liquid crystalline
state, at 550C, the Kp was 14,000 ± 1,600 (SD, n = 14).
Small angle x-ray diffraction
studies
CSL electron density profiles
Membrane multilayers prepared in the presence and
absence of Bay K 8644 at different lipid/drug ratios gave
clearly defined, reproducible diffraction patterns. To
optimize the diffraction quality of our CSL samples, we
examined the multibilayers under a variety of tempera-
ture and hydration conditions. We found that the highest
resolution was obtained at bilayer hydrations of 55 and
66% and low temperatures 5-10°C. At 66% relative
humidity and 60C, for example, we observed six sharp
lamellar diffraction orders with a unit cell repeat distance
of -56 A for a resolution of -9 A (see Table 1). Previous
studies demonstrated strong similiarity in the profile
structures for the intact sarcolemma versus extracted
lipids due to the high lipid-to-protein ratios in the CSL
(Herbette et al., 1985a).
As we further dehydrated the CSL multibilayers below
55% relative humidity, a second lattice of diffraction
peaks along the lamellar meridional axis appears with
peak ratios of 1: XJ3: 2: sfi suggestive of HI, phase lipid
(Gruner, 1985). The HI, phase was also observed when
the temperature was gradually raised above 1 OOC at these
lower relative humidities (55 and 66%). The hexagonal
phase reversibly disappeared as the temperature was
again reduced below 10°C. The phase transition may
compensate for the increase in free energy of this hetero-
genous lipid system as a result of significant increases in
repulsive electrostatic, hydration, and steric forces as the
apposing bilayers come closer together as previously
described in detail (Gruner, 1985; Kirk et al., 1984). For
example, the interbilayer pure water space at 55% rela-
RESULTS
Partition coefficients
The partition coefficient, Kp, for [3H] Bay K 8644 in LSR
was determined to be 10,700 by a graph of log Kp vs. -log
[drug concentration (M)]. This Kp was independent of
drug concentration over the range of 1 x 10' m to 1 x
10-'1 M. This is in agreement with Kp values reported for
other DHPs (Herbette et al., 1986). The octanol/buffer
partition coefficient, on the other hand, was determined to
be 290 ± 10 (SD, n = 3). The partition coefficient of Bay
TABLE 1 Structure factors for CSL in the absence and
presence of Bay K 8644/Bay P 8857, d = 56 A
Absence of
Bay K 8644/Bay P Presence of Presence of
8857 Bay K 8644 Bay P 8857
(h) F(h) (h) F(h) (h) F(h)
1 -0.7979 1 -0.7810 1 -0.7854
2 -0.0979 2 -0.0943 2 -0.0807
3 +0.0458 3 0.0 3 0.0
4 -0.5473 4 -0.5340 4 -0.5148
5 +0.1438 5 +0.1533 5 +0.1757
6 -0.1772 6 -0.2691 6 -0.2842
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tive humidity is only 4.6 A and the pressure exerted
between the bilayers under these conditions is In 17.5
dyns/cm2 by the equations of McIntosh et al. (1987).
P = RT/V.[ln (P/P.)],
in which R is the molar gas constant, T is temperature, V,w
is the molar volume of water (18 cm3/mol), and P/PO is
the relative vapor pressure (McIntosh et al., 1987;
Mason, R. P., and D. W. Chester, submitted for publica-
tion).
Examination of the membrane profile structures in the
presence and absence of drug demonstrates that control
and drug-containing profiles are identical in unit cell
repeat distance (see Figs. 3-6). The bilayer does not
appear to be significantly perturbed by the DHPs at 1:40
and 1:35 drug-lipid concentrations (Bay K 8644 and Bay
P 8857 representing 1% of the membrane mass). This
observation is supported by the consistency in unit cell
repeat distances over a range of drug:lipid ratios and very
similar electron density profiles with the exception of the
following features. Calculated step-function equivalent
profiles indicate the phosphate headgroups are displaced
outward by 1 A by the presence of the agonist in the
bilayer without affecting the calculated 7.5 A width of the
headgroup (Figs. 5 and 6). There is a significant increase
in electron density approximately located at x = ±16.5 A
2.00 -
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-28.0 0.0
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FIGURE 3 One-dimensional electron density profile of a CSL lipid
bilayer in the presence of the DHP antagonist Bay P 8857 with a 1:35
drug:lipid molar ratio. A unit cell repeat distance of 56 A was measured
at 66% relative humidity and 60C. Arrow indicates the putative position
of the iodinated antagonist which is similar to that observed for Bay K
8644 in Fig. 4 within the limits of our resolution.
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FIGURE 4 Distance across a single bilayer unit cell (A) vs. electron
density for purified cardiac sarcolemmal lipid membrane in the presence
and absence of Bay K 8644 at 66% relative humidity and 60C.
Superimposition of the one-dimensional electron density profiles shows a
significant increase in the hydrocarbon core of the bilayer adjacent to
the headgroup (within the first few methylene segments) which we
attribute to the equilibrium location of the Bay K 8644.
from the center of the bilayer corresponding to the first
few methylene segments of the acyl chains (Fig. 7). This
discrete increase in electron density is attributed to the
triflouromethyl substituent of the Bay K 8644 molecule.
This equilibrium position is present over a variety of drug
concentrations (DHP:lipid molar ratios of 1:10 to 1:40,
which correlate well with the relative changes in electron
density) and bilayer hydrations (55-81%). Fig. 3 demon-
strates that Bay P 8857 has a similar location, within the
resolution of our system, as the Bay K 8644.
DPPC electron density profiles
Drug location was examined in DPPC vesicles above and
below its thermal phase transition (see Table 2 and Figs. 1
and 2). The state of the lipids was shown to change from
gel to liquid crystalline state by calculating the unit cell
repeat distance, D, as previously described (Franks and
Lieb, 1979). The D spaces for DPPC bilayers above and
below the phase transition temperature were 52 and 61 A,
respectively. This significant decrease in intrabilayer
thickness is attributed to chain melting in the hydrocar-
bon core of the bilayer with trans to gauche conformation
changes as the system is heated above its Tm. The change
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FIGURE 5 Distance across a single bilayer (A) vs. electron density for
purified cardiac sarcolemmal lipid membrane in the absence of Bay K
8644 at 66% relative humidity and 60C. The peaks in the one-
dimensional electron density profile (-) refer to the phosphate head-
groups (labeled "P"), whereas the central trough of minimum electron
density corresponds to the terminal methyl groups in the bilayer center.
The measured unit cell repeat distance was 56 A. The experimental
profile was modeled (---) with a series of four unique steps (headgroup
region, acyl chains, terminal trough, and water space) with widths
determined by the resolution of the system as described in the Methods
and previously explained in detail (White and King, 1985). The electron
density profile calculated from the modeled step function is superim-
posed on the experimental profile (.... ).
in D space as a function of heating the sample was very
sharp and reproducible. The correlation between change
in D space and change in the physical state from gel to
liquid crystalline has been well described in the litera-
ture.
In the liquid crystalline state, a statistically significant
change in electron density is attributed to the trifluori-
nated "tag" in a location consistent with that observed for
CSL below the phosphate head group (Fig. 2). Below the
thermal phase transition, the lipids are highly ordered in
the gel state resulting in higher resolution diffraction (9
A) at 81% relative humidity. The electron density profiles
for the drug sample and control are similar throughout
the bilayer in the gel state with a significant increase in
electron density located in the interbilayer water space
only (Fig. 1). These results suggest the drug is excluded or
"frozen out" of the bilayer during a change from liquid
crystalline to gel physical state. This extrusion is revers-
ible when the bilayer is returned to the liquid crystalline
state and was independent of bilayer relative humidity
(66-93%).
FIGURE 6 One-dimensional electron density profile of a CSL lipid
bilayer in the presence of Bay K 8644 with a 1:40 drug:lipid molar ratio
at 66% relative humidity and 60C. Relative to the control, the only
significant increase in electron density was modeled by a discrete step
(arrow) with a center of mass ± 16.5 A from the bilayer center
attributed to the halogenated Bay K 8644 molecule. Further, the step
specifically modeling the phospholipid headgroup was displaced out-
ward by -1 A while maintaining its width of 7.5 A. The unit cell repeat
distance is identical to the control (56 A) and the profile is on the same
scale as in Fig. 5. The electron density calculated from the modeled step
function is superimposed on the experimental profile (..... ).
DISCUSSION
To examine the nonspecific membrane interactions of
Bay K 8644, the partition coefficient and the molecular
location have been studied in both biological and model
membrane systems. We suggest for this study (see also
Marqusee and Dill, 1986) that the anisotropic bilayer
structure, in contrast to a bulk phase solvent such as
octanol with invariant properties throughout, has very
different physical and chemical characteristics as a func-
tion of distance across the bilayer normal axis which will
affect drug-lipid interaction. The bilayer also differs from
isotropic solvents because of its high surface-to-volume
ratio. Drug partitioning and location in the bilayer would
be expected to exploit these differences in achieving an
energetically favorable location, orientation, and confor-
mation (Simon et al., 1979; Herbette et al., 1986). For
example, the partitioning of Bay K 8644 into LSR
membranes was nearly two orders of magnitude greater
than in the octanol/buffer system, similar to that
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FIGURE 7 Summary of location for Bay K 8644 in CSL and DPPC in
the liquid crystalline state and for Bay K 8644 in DPPC in the gel state.
The electron density profile is correlated with a hypothetical membrane
bilayer with a transmembrane protein. The Bay P 8857 has a similar
membrane location as the Bay K 8644 in CSL (Figs. 3 and 4).
observed for Bay P 8857 (Herbette et al., 1986). Bay K
8644 partitioning is further affected by the thermal phase
transition of the membrane bilayer. In DPPC mem-
branes, the Kp value was also nearly two orders of
magnitude greater above the thermal phase transition
than below. We would expect this because the membrane
bilayer is highly ordered in the gel phase with acyl chains
in the all-trans conformation resulting in an increase in
lipid density with exclusion of most of the drug from the
bilayer (Fig. 1). As the membrane is melted, the bilayer
becomes less ordered, as indicated by the change in D
space from 61 to 52 A, with a subsequent reduction in
lipid packing density permitting higher drug partitioning
into the bilayer. Similar effects on solute partitioning was
recently described for benzene (DeYoung and Dill,
1988).
The results of low-angle x-ray scattering of Bay K 8644
with DPPC in the gel and liquid crystalline states corre-
late well with these drug partition studies. At -9 A
resolution (81% relative humidity), there is no observable
difference in the electron density profiles for the control
vs. drug samples except for an increase in electron density
indicating the presence of drug in the interbilayer water
space (Fig. 1). Above the thermal phase transition, how-
ever, the interbilayer increase in electron density disap-
pears, whereas there is an increase within the bilayer
(Fig. 2) consistent with the idea that the drug has moved
into the bilayer. This location within the liquid crystalline
DPPC bilayer is consistent with the drug location for the
CSL. Preliminary data has also demonstrated that Bay K
8644 is near the hydrocarbon core/water interface of
dioleoylphosphatidylcholine (DOPC) membranes in the
liquid crystalline state with 8 A resolution.
We have shown that bilayer physical state can play an
important role in drug-membrane interactions. It has
been shown that cholesterol (Genz et al., 1986), alcohols
(O'Leary et al., 1986; Pringle and Miller, 1979), and
fatty acids (Eliasz et al., 1976) effect the ordering and
hence, the thermal phase transition of biological mem-
branes. As such, the presence of these molecules in the
membrane bilayer may significantly affect nonspecific
drug and, further, drug-receptor interactions. It would
also be interesting to consider how the membrane bilayer
structure and drug interactions are influenced by hyper-
cholesterolemia in the disease atherosclerosis, for exam-
ple.
The amphiphilic DHP appears to interact with both the
charged headgroup region and the hydrophobic acyl
chains of the bilayer core. Other drugs and small mole-
cules with greater hydrophobicity can be located either
near or at the central region of the bilayer core such as
alkanes (White et al., 1981; McIntosh et al., 1980) and
amiodarone (Trumbore et al., 1988). The distribution of
solute in membrane bilayers at either of these two regions
TABLE 2 Structure factors for DPPC In the absence and presence of Bay K 8644
At 150C,d - 61 A At 550C,d= 52A
Absence of Bay K 8644 Presence of Bay K 8644 Absence of Bay K 8644 Presence of Bay K 8644
(h) F(h) (h) F(h) (h) F(h) (h) F(h)
1 -0.8819 1 -0.9065 1 -0.9662 1 -0.9562
2 -0.2939 2 -0.2676 2 -0.1277 2 -0.1881
3 +0.2030 3 +0.1808 3 +0.1473 3 +0.1706
4 -0.2912 4 -0.2588 4 -0.1685 4 -0.1453
5 +0.0608 5 +0.0529
6 -0.0500 6 -0.0400
7 +0.0608 7 +0.0490
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appear to be thermodynamically favored over alternative
locations because of enthalpic and entropic constraints
(Marqusee and Dill, 1986).
Bay K 8644's location at the hydrocarbon core/water
interface defines a region of localized drug concentration
that may be in equilibrium with a specific receptor site at
this intrabilayer position. For example, the DHP calcium
channel antagonist, nimodipine, was identified at this
position in sarcoplasmic reticulum using neutron diffrac-
tion (Herbette et al., 1986), whereas Bay P 8857 occupies
a similiar location in CSL lipid bilayers (Fig. 3). This
similar time-averaged location for the agonist and antag-
onist in the membrane may be related to a similiar
high-affinity binding site at this particular depth in the
bilayer (Janis et al., 1984; Hamilton et al., 1987) or
separate binding sites on a structurally related portion of
the receptor involved in the potential sensitive gating
process as described by Kokubun et al. (1986). In either
case these DHPs can laterally diffuse from this position
(Chester et al., 1987) to the hydrophobic receptor site
recently sequenced (Tanabe et al., 1987).
CONCLUSION
An examination of Bay K 8644 partitioning properties
and location in the native and model bilayers reveals that
drug interaction with the membrane bilayer is specific
and is not adequately described by bulk solvent systems,
such as octanol. The disparity between Bay K 8644
partitioning into native bilayers vs. octanol and the effect
of the lipid phase on this partitioning highlights this point.
Further, the consistent location of Bay K 8644 near the
hydrocarbon core/water interface of model and heteroge-
nous lipid bilayer systems in the liquid crystalline state
suggest that the drug-membrane interaction is strongly
influenced by their mutual chemical and physical charac-
teristics. For example, the described time-averaged loca-
tion of Bay K 8644 was dependent on the physical state of
the lipid bilayer. Finally, this partitioning and location is
consistent with the DHP antagonist Bay P 8857 and
suggests a common membrane pathway mechanism for
these drugs en route to a common sarcolemmal receptor.
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